JPWO2019232120A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2019232120A5
JPWO2019232120A5 JP2020566701A JP2020566701A JPWO2019232120A5 JP WO2019232120 A5 JPWO2019232120 A5 JP WO2019232120A5 JP 2020566701 A JP2020566701 A JP 2020566701A JP 2020566701 A JP2020566701 A JP 2020566701A JP WO2019232120 A5 JPWO2019232120 A5 JP WO2019232120A5
Authority
JP
Japan
Prior art keywords
crystal
pharmaceutically acceptable
acceptable salt
composition
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020566701A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021527031A (ja
JP2021527031A5 (https=
JP7778477B2 (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/034505 external-priority patent/WO2019232120A1/en
Publication of JP2021527031A publication Critical patent/JP2021527031A/ja
Publication of JPWO2019232120A5 publication Critical patent/JPWO2019232120A5/ja
Publication of JP2021527031A5 publication Critical patent/JP2021527031A5/ja
Priority to JP2024030700A priority Critical patent/JP7841008B2/ja
Application granted granted Critical
Publication of JP7778477B2 publication Critical patent/JP7778477B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020566701A 2018-05-30 2019-05-30 セピアプテリンの薬学的に許容される塩 Active JP7778477B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024030700A JP7841008B2 (ja) 2018-05-30 2024-02-29 セピアプテリンの薬学的に許容される塩

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201862678025P 2018-05-30 2018-05-30
US62/678,025 2018-05-30
US201862726612P 2018-09-04 2018-09-04
US62/726,612 2018-09-04
US201962822336P 2019-03-22 2019-03-22
US62/822,336 2019-03-22
GC201937661 2019-05-28
GC2019/37661 2019-05-28
PCT/US2019/034505 WO2019232120A1 (en) 2018-05-30 2019-05-30 Pharmaceutically acceptable salts of sepiapterin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024030700A Division JP7841008B2 (ja) 2018-05-30 2024-02-29 セピアプテリンの薬学的に許容される塩

Publications (4)

Publication Number Publication Date
JP2021527031A JP2021527031A (ja) 2021-10-11
JPWO2019232120A5 true JPWO2019232120A5 (https=) 2022-06-07
JP2021527031A5 JP2021527031A5 (https=) 2022-06-07
JP7778477B2 JP7778477B2 (ja) 2025-12-02

Family

ID=68699017

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020566701A Active JP7778477B2 (ja) 2018-05-30 2019-05-30 セピアプテリンの薬学的に許容される塩
JP2024030700A Active JP7841008B2 (ja) 2018-05-30 2024-02-29 セピアプテリンの薬学的に許容される塩

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024030700A Active JP7841008B2 (ja) 2018-05-30 2024-02-29 セピアプテリンの薬学的に許容される塩

Country Status (13)

Country Link
US (1) US20210269443A1 (https=)
EP (1) EP3807279B1 (https=)
JP (2) JP7778477B2 (https=)
KR (1) KR20210038848A (https=)
CN (1) CN112543758A (https=)
AU (2) AU2019277372B2 (https=)
BR (1) BR112020024332A2 (https=)
CA (1) CA3102070A1 (https=)
CL (1) CL2020003101A1 (https=)
CO (1) CO2020016582A2 (https=)
IL (1) IL279101A (https=)
MX (1) MX2020012978A (https=)
WO (1) WO2019232120A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11072614B2 (en) 2016-11-29 2021-07-27 Ptc Therapeutics Mp, Inc. Polymorphs of sepiapterin and salts thereof
US11130760B2 (en) 2016-11-29 2021-09-28 Ptc Therapeutics Mp, Inc. Polymorphic form of sepiapterin
JP7811085B2 (ja) 2017-09-01 2026-02-04 ピーティーシー セラピューティクス エムピー，インコーポレイテッド セピアプテリンを含む医薬組成物及びその使用
EP3801536B1 (en) 2018-05-30 2024-07-17 PTC Therapeutics MP, Inc. Administration of sepiapterin without food for use in a method for increasing sepiapterin plasma exposure
AU2019277372B2 (en) * 2018-05-30 2024-12-19 Ptc Therapeutics Mp, Inc. Pharmaceutically acceptable salts of sepiapterin
CN112654356A (zh) * 2018-05-30 2021-04-13 Ptc医疗Mp公司 增加四氢生物蝶呤血浆暴露的组合物和方法
IL290321B1 (en) 2019-08-05 2026-04-01 Ptc Therapeutics Inc Use of spiapterin and its metabolites for radiation exposure treatment
IL291565B1 (en) 2019-09-25 2026-04-01 Ptc Therapeutics Inc Method for treating phenylalanine irregularity
CA3165636A1 (en) 2020-01-24 2021-07-29 Neil Smith Methods for treating parkinson's disease with sepiapterin
CN114621198B (zh) 2020-12-11 2025-01-21 北京夏禾科技有限公司 有机电致发光材料及其器件
JP2024506336A (ja) 2021-02-09 2024-02-13 ピーティーシー セラピューティクス エムピー，インコーポレイテッド 膠芽腫の治療方法
EP4291196A1 (en) 2021-02-09 2023-12-20 PTC Therapeutics MP, Inc. Methods for treating covid-19 with sepiapterin

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5910304A (en) 1982-12-13 1999-06-08 Texas A&M University System Low-dose oral administration of interferons
CA1320905C (en) 1986-11-06 1993-08-03 Joseph M. Cummins Treatment of immuno-resistant disease
ATE218345T1 (de) * 1994-08-05 2002-06-15 Suntory Ltd Arzneimittel gegen spinocerebellare degeneration
US6036949A (en) 1998-03-05 2000-03-14 Amarillo Biosciences, Inc. Treatment of fibromyalgia with low doses of interferon
WO2008128049A2 (en) * 2007-04-11 2008-10-23 Biomarin Pharmaceutical Inc. Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring
JP2012512848A (ja) 2008-12-23 2012-06-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 有機化合物の塩の形態
EP2562176B1 (en) 2010-04-22 2018-08-15 Nihon University Medicinal agent and beverage/food for preventing cerebral dysfunction and improving same
IN2014DN09053A (https=) 2012-05-07 2015-05-22 Shiratori Pharm
WO2017218421A1 (en) * 2016-06-13 2017-12-21 Meharry Medical College Modulation of the nitric oxide synthase pathway for oral health
US11130760B2 (en) * 2016-11-29 2021-09-28 Ptc Therapeutics Mp, Inc. Polymorphic form of sepiapterin
US11072614B2 (en) * 2016-11-29 2021-07-27 Ptc Therapeutics Mp, Inc. Polymorphs of sepiapterin and salts thereof
JP7811085B2 (ja) 2017-09-01 2026-02-04 ピーティーシー セラピューティクス エムピー，インコーポレイテッド セピアプテリンを含む医薬組成物及びその使用
AU2019277372B2 (en) * 2018-05-30 2024-12-19 Ptc Therapeutics Mp, Inc. Pharmaceutically acceptable salts of sepiapterin

Similar Documents

Publication Publication Date Title
JP2021527031A5 (https=)
US20250312308A1 (en) Methods of treating neurological and psychiatric disorders
CN109734701B (zh) Rock抑制剂-二氯乙酸复盐及其制备方法和用途
JP7671245B2 (ja) ピリダジノン化合物およびその使用
JPWO2019232120A5 (https=)
JP2024063143A5 (https=)
JP6786086B2 (ja) １，３，５−トリアジン誘導体及びその使用方法
CA2747427C (en) Method for producing diamine derivative
CN101636161A (zh) 1－[2－(2,4－二甲基苯基硫烷基)苯基]哌嗪作为具有结合的5－羟色胺重吸收、5－ht3和5－ht1a活性的化合物用于治疗疼痛或与睡眠和认知有关的抑郁残留症状
WO2023232069A1 (zh) 一种氮杂喹啉酮类衍生物、其制备方法及用途
EA024563B1 (ru) Применение с-мет-модуляторов в комбинированной терапии рака
JPWO2009038112A1 (ja) Ｎｐｙｙ５受容体拮抗剤を含有する固形製剤
JP2023505963A (ja) ケタミンパモエート塩の長時間作用型注射用製剤
WO2019236625A1 (en) Eaat2 activators and methods of using thereof
CN111712503A (zh) 取代的四氢吡喃二氢噻吩并嘧啶类化合物及其作为磷酸二酯酶抑制剂的用途
EP3679016B1 (en) Solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-n-benzylacetamide
CN112174951A (zh) 作为詹纳斯激酶1选择抑制剂的吡咯并[2，3-b]吡啶衍生物
JP2021533080A (ja) 結晶トラニラスト塩およびこれらの医薬的な使用
CN114805263B (zh) 3-(羟基苄基)苯酞类化合物、其制备方法和用途
WO2025107982A1 (zh) 一种吡非尼酮衍生物及其制备方法与应用
JP5888612B2 (ja) 縮合ピリジン化合物塩の結晶
CN113105409B (zh) 2-(羟基苄基)苯并[d]异噻唑酮类化合物、其制备方法和用途
CN117586204A (zh) 异硒唑酮类化合物、其合成方法及用途
US12552737B2 (en) Salts of (2R, 6R)-hydroxynorketamine, their crystal forms, and methods of making the same
TW201400447A (zh) ３－（１５－羥基十五烷基）－２，４，４－三甲基－２－環己烯－１－酮之共結晶